CDK4 and neoplasm: 2) Emergence of CDK4/6 inhibitors: Recent development of selective CDK4/6 inhibitors resulted in, compared with previous generations of CDK inhibitors, lower toxicities, higher tumor-suppressive activities, and enhanced tumor immunogenicity (O'Leary et al., 2016; Goel et al., 2017).